Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication
Metabolic syndrome, a group of cardiovascular risk factors related to insulin resistance, is a major determinant of cardiovascular mortality.
Intermittent claudication is a symptom of an early stage of atherosclerosis.
The aim of this study is to determine the prevalence of the metabolic syndrome in patients with intermittent claudication and its correlation with age, gender, localization of arterial obstruction and association with coronary artery disease.
|Intermittent Claudication Metabolic Syndrome X|
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication|
- Presence of metabolic syndrome in patients with intermittent claudication [ Time Frame: After laboratory exams results. ]
- Correlation of metabolic syndrome with age, sex, localization of the arterial obstruction and the association with symptomatic coronary artery disease. [ Time Frame: At the end of data collection ]
|Study Start Date:||May 2009|
|Study Completion Date:||July 2009|
|Primary Completion Date:||July 2009 (Final data collection date for primary outcome measure)|
Intermittent claudication patients
Patients with intermittent claudication with metabolic syndrome and patients with intermittent claudication without metabolic syndrome.
Studies correlating metabolic syndrome and several illnesses are being published, especially affections associated with atherosclerosis, like coronary artery disease, cerebrovascular disease and peripheral arterial disease.
The term peripheral arterial disease, however, refers to several stages of the development of atherosclerosis in the extremities, comprising since asymptomatic patients as far as individuals with critical ischemia.
Intermittent claudication is a symptom of an early stage of atherosclerosis, when medical interventions may still prevent the progression of the disease. Despite the importance of a precocious diagnosis of metabolic syndrome to initiate adequate treatment, its prevalence among these patients is not well determined in the literature.
This is the biggest casuistic in the literature as far as we know.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00946868
|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo|
|Sao Paulo, SP, Brazil, 05403 000|
|Principal Investigator:||Nelson Wolosker, PhD||University of Sao Paulo|
|Study Chair:||Pedro P Leao, PhD||University of Sao Paulo|